How to Choose the Best Disease Modeling Systems for Your Lab

Choosing disease modeling systems is not a shopping exercise. It is a decision about which biological features your experiment must preserve. A tumor spheroid can reveal gradients in oxygen and drug penetration. A patient-derived organoid may capture some tissue-specific responses, yet miss immune and vascular interactions. No model reproduces a whole patient. That limitation deserves attention, not a footnote.

The evidence base is evolving. IQVIA Institute’s Global Trends in R&D 2024 report tracks changes in biopharmaceutical research and development, while FDA guidance on regulatory science discusses the role of new methods in nonclinical evaluation. These sources offer useful context, but neither can select a model for your exact question. Statistician George E. P. Box’s well-known reminder applies: “All models are wrong, but some are useful.” For a lab, usefulness means fit for purpose, reproducibility, and a clear account of what the system cannot represent.

Start with the decision your study must support. Compare models by human relevance, experimental control, throughput, cost, and access to validated protocols. Then inspect practical details: cell provenance, passage limits, matrix composition, assay compatibility, and batch-to-batch variation. Ask whether results can be repeated by another researcher, not only by the original team. NCATS’s Tissue Chip for Drug Screening program illustrates how engineered human-relevant systems can support this broader effort, but a sophisticated platform is not automatically the right one. It may be too complex, too costly, or poorly matched to your endpoint. A thoughtful choice makes those trade-offs visible—and leaves room to revise the plan when evidence disagrees.

Table of Contents [Hide]

1 Define the Research Question and Required Disease Features

2 Compare Available Disease Modeling System Types

3 Assess Model Validity, Reproducibility, and Limitations

4 Evaluate Costs, Expertise, and Laboratory Requirements

5 Select and Validate the Best-Fit System for Your Study

Define the Research Question and Required Disease Features

How to Choose the Best Disease Modeling Systems for Your Lab

Define the Research Question and Required Disease Features

Begin with the biological claim your study must test. Are you examining a gene variant, immune-cell interaction, drug response, or disease progression? Then list the features the model must reproduce, such as tissue architecture, relevant cell types, metabolic activity, or a measurable symptom. A model can resemble a disease without capturing its key mechanism. That distinction matters. In a 2016 Nature survey of 1,576 researchers, more than 70% reported failing to reproduce another researcher’s experiments (Baker, “1,500 scientists lift the lid on reproducibility,” Nature). The survey is not specific to disease models, but it highlights why methods and assumptions need careful scrutiny. Define measurable outcomes before choosing a system: for example, a change in cytokine levels, lesion size, or cell survival over a stated period. Match these endpoints to the research question, not just to available equipment.

Tips: Write down three essential disease features and one feature your model cannot capture. Check whether the proposed system has evidence for each essential feature, including published validation and known limitations. A simple table can expose gaps. Be candid about uncertainty; model selection is rarely tidy, and I would reassess the choice if the central endpoint depends on a feature the system lacks.

How to Choose the Best Disease Modeling Systems for Your Lab – Define the Research Question and Required Disease Features

Modeling system	Disease features it can represent	Useful research questions	Key strengths	Important limitations	Best fit when the priority is…
2D cell culture	Cell-autonomous processes, such as signaling, gene expression, and responses to a defined stimulus.	Does a specific gene, pathway, or compound change a measurable cellular response?	Straightforward to control, image, and scale for experiments; often suitable for screening.	Usually lacks tissue architecture, systemic physiology, and many cell–cell or matrix interactions.	Testing a focused mechanism or comparing many conditions efficiently.
Primary cells	Some functions of cells obtained from tissue, potentially including donor-specific characteristics.	Does a finding hold in a more physiologically relevant cell type or across donors?	Can retain features of the source tissue that established cell lines may not preserve.	Availability, donor variation, limited expansion, and changes during culture can constrain experiments.	Confirming cell-type-specific findings while accounting for donor variability.
Organoids and other 3D cultures	Selected aspects of tissue organization, differentiation, and interactions among cells in three-dimensional structures.	How does a tissue-like structure respond to disease-associated changes or treatment?	Can capture features of tissue architecture and cellular diversity that are absent from standard 2D culture.	May lack blood vessels, immune components, or other systemic influences; protocols and results can vary.	Studying tissue-level behavior in a controllable in vitro setting.
Induced pluripotent stem cell (iPSC)-derived models	Selected cell types generated from donor-derived cells; some lines can carry disease-associated genetic backgrounds.	How does a genetic variant or donor background affect a cell type relevant to the disease?	Can support comparisons between genetic backgrounds and generation of otherwise difficult-to-access cell types.	Differentiation may be incomplete or variable; the model may not reproduce adult tissue maturity or the full disease process.	Investigating human genetic contributions in a defined cell type.
Animal models	Interactions among organs and systems, including aspects of physiology, behavior, and whole-organism responses.	Does a mechanism or intervention affect disease-related outcomes in an intact organism?	Enables measurement of integrated biological processes that isolated cell systems cannot reproduce.	Species differences can limit translation to humans; experiments require careful ethical review and welfare planning.	Testing organism-level effects when the research question requires integrated physiology.
Computational or in silico models	Relationships represented in available data, such as predicted pathways, molecular interactions, or population-level patterns.	Which hypotheses, targets, or experiments should be prioritized based on existing evidence?	Can integrate large datasets and explore predictions before conducting laboratory experiments.	Predictions depend on data quality and model assumptions; computational results require appropriate validation.	Prioritizing hypotheses or analyzing complex datasets efficiently.

Selection principle: choose the simplest model that captures the disease features essential to the research question, then validate key findings in a complementary system when appropriate.

Compare Available Disease Modeling System Types

Disease models differ in what they preserve. Cell cultures are relatively simple to maintain and useful for testing pathways, doses, and repeatable measurements. A flat layer of cells, however, may miss interactions with surrounding tissue. Small differences in cell source or passage number can also shift results.

Organoids add three-dimensional structure and can capture features of a tissue more realistically. They may help researchers study disease variation or responses to treatment, but growth conditions and batch-to-batch differences require careful tracking. Not a perfect miniature. Animal models include whole-body processes, such as immune and metabolic interactions, that cell systems cannot reproduce. Yet species differences can limit how well results translate to people, and these studies generally need more time, resources, and ethical review.

Computational models can integrate clinical, molecular, or experimental data to explore patterns and generate testable predictions. Their reliability depends on data quality and assumptions; a clean-looking output can still rest on weak inputs. The right comparison starts with the research question: Which biological feature must the model retain, and what evidence would show it does? Many labs combine systems, checking a promising signal in a second model before drawing strong conclusions. That extra step can be inconvenient. It may also expose a result that only appears in one carefully controlled setup.

Assess Model Validity, Reproducibility, and Limitations

Choosing a disease model starts with validity, not convenience. In practice, a model should reproduce the human feature that matters: a scarred matrix, altered glucose levels, or a measurable immune response. Face validity looks similar. Construct validity tests the underlying biology. Predictive validity asks whether results can guide clinical decisions. These are different questions.

Reproducibility deserves equal weight. A 2016 survey of 1,576 researchers reported that more than 70% had failed to reproduce another scientist’s results. Over half viewed reproducibility as a major problem. Build a written protocol before experiments begin. Record passage number, donor characteristics, media changes, matrix stiffness, and exclusion rules. Randomization and blinded image analysis can reduce quiet bias. Independent replication is stronger than repeating one successful run.

Limitations must stay visible. Species differences can distort drug responses. Cell lines may drift after repeated passage. Primary cells can vary sharply between donors. Even small temperature changes can affect organoid growth. A model may be biologically elegant yet clinically weak. The National Academies’ reproducibility guidance emphasizes transparent methods, complete reporting, and data sharing. Still, reporting everything does not remove biological noise. I have seen teams overinterpret a clean graph from one batch. That is a warning, not proof. A useful model is one whose failures are measurable, explainable, and honestly carried into the next experiment.

Evaluate Costs, Expertise, and Laboratory Requirements

A disease model is only useful when your lab can run it consistently. Start with the question, then list the equipment, staff time, and space it requires. A cell-based model may need sterile culture facilities and regular imaging. An animal model can require specialized housing, trained personnel, and longer approval and study timelines. Check these needs against your actual capacity, not an ideal future budget. Small details matter. A shared microscope can become a bottleneck.

Cost estimates should include more than purchase price. Count consumables, training, quality checks, maintenance, and the time needed to interpret results. A 2015 analysis by Freedman and colleagues estimated that irreproducible preclinical research costs the United States about $28 billion annually. That figure is not a price comparison between modeling systems. It does underline the value of validated protocols, clear controls, and staff expertise. Ask whether your team can repeat the model across operators and batches. Be honest about gaps. A model that looks impressive but depends on one person’s undocumented technique may not be a sound investment.

Before committing, map each model’s requirements to your lab’s workflow: bench space, biosafety procedures, data storage, and access to specialist support. Request pilot data or run a small feasibility study with predefined success criteria. Record setup time and failed runs, too. They count. Published performance may not transfer neatly to your samples or equipment, and that uncertainty deserves room in the budget.

Scores are qualitative planning estimates on a 1–5 scale, where 1 indicates lower requirements and 5 indicates higher requirements. Actual costs and capabilities vary by model, research question, and facility; these ratings are not market-price data.

Select and Validate the Best-Fit System for Your Study

How to Choose the Best Disease Modeling Systems for Your Lab

Select and Validate the Best-Fit System for Your Study

A useful disease model should answer a specific question, not simply resemble a human condition. Define the decision your experiment must support: mechanism, target response, toxicity, or patient stratification. Then compare candidate systems against that decision. A cell line may offer clean, repeatable results, while primary cells can better reflect donor variation. Organoids add tissue-like structure, but their maturity and batch consistency require careful checks. Small details matter. Record passage number, culture conditions, and assay timing; each can shift an apparent effect.

Validate the model before scaling up. Confirm identity, relevant markers, and baseline behavior, then test whether a known stimulus produces an expected response. Include positive and negative controls, replicate across independent batches, and set acceptance criteria before reviewing results. These steps cannot guarantee clinical relevance. They can reveal when a model is answering a narrower question than intended. The BIO, Informa Pharma Intelligence, and QLS Advisors report, Clinical Development Success Rates and Contributing Factors 2011–2020, estimated an overall likelihood of approval of 7.9% across clinical development. That figure spans many causes of failure, so it should not be read as a direct measure of model quality. Still, it underscores why a promising signal in one system needs cautious interpretation. Sometimes the best choice is less elegant—and more reproducible.